{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:36:10Z","timestamp":1790728570826,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Enfermedades infecciosas y microbiologia clinica (English ed.)"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.eimce.2024.05.009","type":"journal-article","created":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T10:47:35Z","timestamp":1716115655000},"page":"71-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dalbavancin as consolidation antibiotic treatment in infective endocarditis, cardiac implantable electronic devices infection and bacteremia: Clinical experience of 7 years"],"prefix":"10.1016","volume":"43","author":[{"given":"Alejandro","family":"Salinas-Botr\u00e1n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Olmos-Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fern\u00e1ndez de Velasco-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Guzm\u00e1n-Carreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Morales-Rosas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"G\u00f3mez-Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimce.2024.05.009_bib0005","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1016\/j.jacc.2017.10.005","article-title":"The evolving nature of infective endocarditis in Spain: a population-based study","volume":"70","author":"Olmos","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.eimce.2024.05.009_bib0010","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jacc.2016.10.052","article-title":"Evolution of prognosis in left-sided infective endocarditis: a propensity score analysis of 2 decades","volume":"69","author":"Sevilla","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.eimce.2024.05.009_bib0015","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1016\/j.jacc.2012.02.029","article-title":"Temporal trends in infective endocarditis in the context of prophylaxis guideline modifications: three successive population-based surveys","volume":"59","author":"Duval","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.eimce.2024.05.009_bib0020","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/1469-0691.12166","article-title":"Enterococcal endocarditis in the beginning of the 21st century: analysis from the International Collaboration on Endocarditis-Prospective Cohort Study","volume":"19","author":"Chirouze","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.eimce.2024.05.009_bib0025","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1093\/eurheartj\/ehv319","volume":"36","author":"Habib","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.eimce.2024.05.009_bib0030","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eimc.2013.12.002","article-title":"Infecciones relacionadas con el uso de cat\u00e9teres vasculares","volume":"32","author":"Ferrer","year":"2014","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimce.2024.05.009_bib0035","unstructured":"Food and Drug Administration. Drug Trials Snapshot: DALVANCE (dalbavancin). Web FDA; Accessed 26\/02\/2023. Available from: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drug-trials-snapshot-dalvance-dalbavancin."},{"key":"10.1016\/j.eimce.2024.05.009_bib0040","unstructured":"European Medicines Agency. Xydalba (dalbavancin). Web European Medicines Agency. Accessed 26\/02\/2023. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xydalba."},{"key":"10.1016\/j.eimce.2024.05.009_bib0045","doi-asserted-by":"crossref","first-page":"26","DOI":"10.37201\/req\/s01.07.2021","article-title":"Dalbavancina","volume":"34","author":"Barber\u00e1n","year":"2021","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.eimce.2024.05.009_bib0050","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/cid\/civ982","article-title":"A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection","volume":"62","author":"Dunne","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimce.2024.05.009_bib0055","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1128\/AAC.48.3.940-945.2004","article-title":"Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers","volume":"48","author":"Leighton","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimce.2024.05.009_bib0060","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/europace\/euz246","volume":"22","author":"Blomstr\u00f6m-Lundqvist","year":"2020","journal-title":"Europace"},{"key":"10.1016\/j.eimce.2024.05.009_bib0065","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3390\/prosthesis5010012","article-title":"Infection of vascular prostheses: a comprehensive review","volume":"5","author":"Costa","year":"2023","journal-title":"Prosthesis"},{"key":"10.1016\/j.eimce.2024.05.009_bib0070","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1128\/AAC.01021-12","article-title":"Treatment duration for uncomplicated Staphylococcus aureus bacteremia to prevent relapse: analysis of a prospective observational cohort study","volume":"57","author":"Chong","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimce.2024.05.009_bib0075","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1128\/AAC.48.3.1061-1064.2004","article-title":"Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin","volume":"48","author":"Lefort","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimce.2024.05.009_bib0080","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/cid\/ciy279","article-title":"Dalbavancin as primary and sequential treatment for gram-positive infective endocarditis: 2-year experience at the general hospital of Vienna","volume":"67","author":"Tobudic","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimce.2024.05.009_bib0085","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlab099","article-title":"Use of dalbavancin in infective endocarditis: a case series","volume":"3","author":"Guleri","year":"2021","journal-title":"JAC-Antimicrob Resist"},{"key":"10.1016\/j.eimce.2024.05.009_bib0090","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ijid.2019.02.013","article-title":"Multicenter clinical experience of real life Dalbavancin use in gram-positive infections","volume":"81","author":"Wunsch","year":"2019","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.eimce.2024.05.009_bib0095","doi-asserted-by":"crossref","first-page":"700","DOI":"10.3390\/antibiotics9100700","article-title":"Dalbavancin in the treatment of bacteremia and endocarditis in people with barriers to standard care","volume":"9","author":"Ajaka","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.eimce.2024.05.009_bib0100","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1808312","article-title":"Partial oral versus intravenous antibiotic treatment of endocarditis","volume":"380","author":"Iversen","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimce.2024.05.009_bib0105","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/23744235.2017.1296968","article-title":"Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic","volume":"49","author":"Dash","year":"2017","journal-title":"Infect Dis"},{"key":"10.1016\/j.eimce.2024.05.009_bib0110","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ijantimicag.2019.08.006","article-title":"Dalbavancin French Study Group. French national cohort of first use of dalbavancin: a high proportion of off-label use","volume":"54","author":"Dinh","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.eimce.2024.05.009_bib0115","first-page":"959","article-title":"Role of oritavancin in the treatment of infective endocarditis, catheter- or device-related infections, bloodstream infections, and bone and prosthetic joint infections in humans: narrative review and possible developments","volume":"13","author":"Lupia","year":"2023","journal-title":"Life (Basel)"},{"key":"10.1016\/j.eimce.2024.05.009_bib0120","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.cmi.2016.04.003","article-title":"Switch to oral antibiotics in the treatment of infective endocarditis is not associated with increased risk of mortality in non-severely ill patients","volume":"22","author":"Mzabi","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.eimce.2024.05.009_bib0125","first-page":"ciad119","article-title":"Real-world application of oral therapy for infective endocarditis: a multicenter retrospective, cohort study","author":"Freling","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimce.2024.05.009_bib0130","doi-asserted-by":"crossref","first-page":"ofz386","DOI":"10.1093\/ofid\/ofz386","article-title":"Practice patterns of infectious diseases physicians in transitioning from intravenous to oral therapy in patients with bacteremia","volume":"7","author":"Hospenthal","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.eimce.2024.05.009_bib0135","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12941-019-0329-6","article-title":"DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and\/or bloodstream infection produced by gram-positive cocci","volume":"18","author":"Hidalgo-Tenorio","year":"2019","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.eimce.2024.05.009_bib0140","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02280-18","article-title":"Safety and efficacy of prolonged use of dalbavancin in bone and joint infections","volume":"63","author":"Morata","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimce.2024.05.009_bib0145","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.04550-14","article-title":"Extended-duration dosing and distribution of dalbavancin into bone and articular tissue","volume":"59","author":"Dunne","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimce.2024.05.009_bib0150","first-page":"151","article-title":"Dalbavancina como tratamiento antibi\u00f3tico supresor. A prop\u00f3sito de 1 caso","volume":"34","author":"Barbero","year":"2021","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.eimce.2024.05.009_bib0155","doi-asserted-by":"crossref","first-page":"ofz427","DOI":"10.1093\/ofid\/ofz427","article-title":"Serum bactericidal activity levels monitor to guide intravenous dalbavancin chronic suppressive therapy of inoperable staphylococcal prosthetic valve endocarditis: a case report","volume":"6","author":"Spaziante","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.eimce.2024.05.009_bib0160","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.eimc.2009.08.002","article-title":"Infecci\u00f3n de pr\u00f3tesis articulares y materiales de osteos\u00edntesis: efectos secundarios de linezolid en uso prolongado","volume":"28","author":"Salinas-Botr\u00e1n","year":"2010","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimce.2024.05.009_bib0165","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/icvts\/ivy127","article-title":"Surgery for acute infective endocarditis: epidemiological data from a Spanish nationwide hospital-based registry","volume":"27","author":"Bustamante-Munguira","year":"2018","journal-title":"Interact CardioVasc Thorac Surg"},{"key":"10.1016\/j.eimce.2024.05.009_bib0170","unstructured":"Ministerio de Sanidad. Gobierno de Espa\u00f1a. Costes hospitalarios. Contabilidad anal\u00edtica [Internet]. Web Ministerio de Sanidad; Accessed 26\/2\/2023. Available from: https:\/\/www.mscbs.gob.es\/estadEstudios\/estadisticas\/inforRecopilaciones\/anaDesarrolloGDR.htm."},{"key":"10.1016\/j.eimce.2024.05.009_bib0175","doi-asserted-by":"crossref","unstructured":"Subdirecci\u00f3n General de Informaci\u00f3n Sanitaria y Evaluaci\u00f3n. Direcci\u00f3n General de Salud P\u00fablica, Calidad e Innovaci\u00f3n Estad\u00edstica de Centros Sanitarios de Atenci\u00f3n Especializada. Hospitales y Centros sin Internamiento. A\u00f1o 2016 [Publicaci\u00f3n en Internet]. Madrid: Ministerio de Sanidad, Consumo y Bienestar Social, 2018. DOI: https:\/\/doi.org\/10.1016\/j.eimc.2009.08.002.","DOI":"10.1016\/j.eimc.2009.08.002"},{"key":"10.1016\/j.eimce.2024.05.009_bib0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106749","article-title":"Dalbavancin as sequential therapy for infective endocarditis due to Gram-positive organisms: a review","volume":"61","author":"Fazili","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.eimce.2024.05.009_bib0185","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ijid.2023.11.003","article-title":"Comparison of dalbavancin with standard of care in the management of infective endocarditis: efficacy, safety, and cost analysis","volume":"138","author":"Su\u00e1rez","year":"2024","journal-title":"Int J Infect Dis."}],"container-title":["Enfermedades infecciosas y microbiologia clinica (English ed.)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2529993X2400128X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2529993X2400128X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T22:14:54Z","timestamp":1738707294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2529993X2400128X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2529993X2400128X"],"URL":"https:\/\/doi.org\/10.1016\/j.eimce.2024.05.009","relation":{},"ISSN":["2529-993X"],"issn-type":[{"value":"2529-993X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dalbavancin as consolidation antibiotic treatment in infective endocarditis, cardiac implantable electronic devices infection and bacteremia: Clinical experience of 7 years","name":"articletitle","label":"Article Title"},{"value":"Enfermedades infecciosas y microbiologia clinica (English ed.)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eimce.2024.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.eimc.2024.02.010","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}